128 related articles for article (PubMed ID: 11295632)
1. Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer.
Weiss HL; Urban DA; Grizzle WE; Cronin KA; Freedman LS; Kelloff GJ; Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):220-3. PubMed ID: 11295632
[TBL] [Abstract][Full Text] [Related]
2. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of biomarker modulation by fenretinide in prostate cancer patients.
Urban D; Myers R; Manne U; Weiss H; Mohler J; Perkins D; Markiewicz M; Lieberman R; Kelloff G; Marshall M; Grizzle W
Eur Urol; 1999; 35(5-6):429-38. PubMed ID: 10325501
[TBL] [Abstract][Full Text] [Related]
4. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate.
Pienta KJ; Esper PS; Zwas F; Krzeminski R; Flaherty LE
Am J Clin Oncol; 1997 Feb; 20(1):36-9. PubMed ID: 9020285
[TBL] [Abstract][Full Text] [Related]
5. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system.
Slawin K; Kadmon D; Park SH; Scardino PT; Anzano M; Sporn MB; Thompson TC
Cancer Res; 1993 Oct; 53(19):4461-5. PubMed ID: 8402613
[TBL] [Abstract][Full Text] [Related]
6. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
7. Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers.
Soria JC; Moon C; Wang L; Hittelman WN; Jang SJ; Sun SY; Lee JJ; Liu D; Kurie JM; Morice RC; Lee JS; Hong WK; Mao L
J Natl Cancer Inst; 2001 Aug; 93(16):1257-63. PubMed ID: 11504771
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
9. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium.
Kurie JM; Lee JS; Khuri FR; Mao L; Morice RC; Lee JJ; Walsh GL; Broxson A; Lippman SM; Ro JY; Kemp BL; Liu D; Fritsche HA; Xu X; Lotan R; Hong WK
Clin Cancer Res; 2000 Aug; 6(8):2973-9. PubMed ID: 10955773
[TBL] [Abstract][Full Text] [Related]
10. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.
Gee JR; Saltzstein DR; Messing E; Kim K; Kolesar J; Huang W; Havighurst TC; Harris L; Wollmer BW; Jarrard D; House M; Parnes H; Bailey HH
Eur J Cancer Prev; 2016 Jul; 25(4):312-20. PubMed ID: 26313229
[TBL] [Abstract][Full Text] [Related]
11. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
12. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
13. Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.
Torrisi R; Mezzetti M; Johansson H; Barreca A; Pigatto F; Robertson C; Decensi A
Int J Cancer; 2000 Aug; 87(4):601-5. PubMed ID: 10918204
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide.
Jinno H; Steiner MG; Mehta RG; Osborne MP; Telang NT
Carcinogenesis; 1999 Feb; 20(2):229-36. PubMed ID: 10069458
[TBL] [Abstract][Full Text] [Related]
15. Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia.
Clark LC; Marshall JR
Urology; 2001 Apr; 57(4 Suppl 1):185-7. PubMed ID: 11295623
[TBL] [Abstract][Full Text] [Related]
16. Target populations and strategies for chemoprevention trials of prostate cancer.
Bostwick DG
J Cell Biochem Suppl; 1994; 19():191-6. PubMed ID: 7823591
[TBL] [Abstract][Full Text] [Related]
17. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
[TBL] [Abstract][Full Text] [Related]
18. 4-(hydroxyphenyl)retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland.
Green A; Shilkaitis A; Christov K
Carcinogenesis; 1999 Aug; 20(8):1535-40. PubMed ID: 10426803
[TBL] [Abstract][Full Text] [Related]
19. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovich L; Malone WA; Crowell JA; Higley HR; Sigman CC
Urology; 2001 Apr; 57(4 Suppl 1):46-51. PubMed ID: 11295594
[TBL] [Abstract][Full Text] [Related]
20. Is There a Future for Chemoprevention of Prostate Cancer?
Bosland MC
Cancer Prev Res (Phila); 2016 Aug; 9(8):642-7. PubMed ID: 27099271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
